BreezeBio develops gene therapies and gene-editing solutions using a CRISPR delivery system built from engineered CRISPR components and a proprietary polymer nanoparticle library. It packages CRISPR components into polymer nanoparticles that deliver Cas9 and guide RNAs to target cells, enabling tissue-specific gene edits. The company differentiates itself by combining in-house polymer nanoparticle technology with component-level CRISPR engineering, supported by proof-of-concept data and industry partnerships. Its goal is to commercialize the delivery platform and resulting therapeutics through licensing, partnerships, and direct sales to medical and healthcare clients.
Company Size
51-200
Company Stage
Series B
Total Funding
$118.5M
Headquarters
Brisbane, California
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?